Does Intrathecal Baclofen Therapy Lead to an Improvement in Impairments and Functional Limitations in Patients With Acquired Brain Injury (ABI)? A Retrospective Study

2021 ◽  
Vol 102 (10) ◽  
pp. e25
Author(s):  
Sejal Patel ◽  
Laura Fazzari
Medicine ◽  
2017 ◽  
Vol 96 (34) ◽  
pp. e7472 ◽  
Author(s):  
Young Kwon Yoon ◽  
Kil Chan Lee ◽  
Han Eol Cho ◽  
Minji Chae ◽  
Jin Woo Chang ◽  
...  

Brain Injury ◽  
2013 ◽  
Vol 27 (13-14) ◽  
pp. 1671-1675 ◽  
Author(s):  
Federico Posteraro ◽  
Benedetta Calandriello ◽  
Rosita Galli ◽  
Fiammetta Logi ◽  
Laura Iardella ◽  
...  

2018 ◽  
Vol 61 ◽  
pp. e307
Author(s):  
V. Charton ◽  
F. Frémondière ◽  
M. Delion ◽  
P. Van Bogaert ◽  
Gignoux ◽  
...  

1997 ◽  
Vol 87 (3) ◽  
pp. 415-419 ◽  
Author(s):  
Jay M. Meythaler ◽  
Anne McCary ◽  
Mark N. Hadley

✓ Twelve consecutive patients with severe spasticity and hypertonia following acquired brain injury were treated with continuous intrathecal infusion of baclofen via an implanted, programmable infusion pump—catheter system for a minimum of 3 months. In every case intrathecal baclofen therapy resulted in a statistically significant reduction in upper- and lower-extremity tone, spasm frequency, and reflexes, contributing to improved functional abilities. There were no untoward side effects or complications associated with treatment. This preliminary assessment indicates that intrathecal administration of baclofen is effective in treating the disabling spasticity caused by acquired brain injury in selected patients.


Sign in / Sign up

Export Citation Format

Share Document